AZD5335 + bevacizumab

AZD5335 + bevacizumab is an investigational combination regimen comprising AZD5335, a folate receptor alpha (FRα)-targeted antibody-drug conjugate (ADC), co-administered with bevacizumab, a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A). AZD5335 selectively targets cancer cells expressing FRα and delivers a topoisomerase 1 inhibitor payload to induce cytotoxicity, while bevacizumab suppresses angiogenesis by blocking VEGF-A, thereby reducing tumor blood supply. This combination is being studied primarily for the treatment of advanced solid tumors such as ovarian cancer and lung adenocarcinoma in Phase I/IIa trials, with both drugs administered intravenously. Developed by AstraZeneca, the combination aims to enhance anti-tumor efficacy by exploiting both targeted cytotoxicity and anti-angiogenic mechanisms.[1][3][5][7][9]

Other names

AZD5335 + Avastin